AbCellera Biologics Inc (ABCL) Q3 2025 Earnings Call Highlights: Transition to Clinical-Stage …
This article first appeared on GuruFocus. Release Date: November 06, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. AbCellera Biologics Inc (NASDAQ:ABCL) has successfully transitioned from a platform company to a clinical-stage biotech, with phase one clinical trials for ABCL 635 and ABCL 575 underway. The…